References

Appert-Collin, A., Hubert, P., Crémel, G. & Bennasroune, A. 2015. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Frontiers in Pharmacology, 6.

Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E. & Shepard, H. M. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences, 89, 4285-4289.

Cassady, J. M., Chan, K. K., Floss, H. G. & Leistner, E. 2004. Recent Developments in the Maytansinoid Antitumor Agents. Chemical and Pharmaceutical Bulletin, 52, 1-26.

Chari, R. J., Goldmacher, V. S., Lambert, J. M. & Blattler, W. A. 1992. Cytotoxic agents comprising maytansinoids and their therapeutic use. US 07/986,578. 04/05/1993.

Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., Green, M. & Gianni, L. 2017. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology, 18, 732-742.

EMA. 2023. Kadcyla [Online]. European Medicines Agency. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla [Accessed 21/10/2024 2024].

EMA. 2024. EPAR - Product Information, Herceptin [Online]. European Medicines Agency. Available: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf [Accessed 22/10/2024].

FDA. 1998. Herceptin [Online]. U.S. Food and Drug Administration. Available: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792 [Accessed 22/10/2024].

Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. 2022. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther, 7, 93.

Gullick, W. J. 2001. Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer. Breast Cancer Res, 3, 390-4.

Hsu, J. L. & Hung, M. C. 2016. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev, 35, 575-588.

Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. 2020. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel), 13.

Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U. & Zhang, J. 2020. Antibody–Drug Conjugates: A Comprehensive Review. Molecular Cancer Research, 18, 3-19.

Kupchan, S. M., Komoda, Y., Court, W. A., Thomas, G. J., Smith, R. M., Karim, A., Gilmore, C. J., Haltiwanger, R. C. & Bryan, R. F. 1972. Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. Journal of the American Chemical Society, 94, 1354-1356.

Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V. & Lutz, R. J. 2008. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer research, 68, 9280-9290.

Loibl, S. & Gianni, L. 2017. HER2-positive breast cancer. The Lancet, 389, 2415-2429.

Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S., Widdison, W., Chari, R. & Jordan, M. A. 2010. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. Molecular Cancer Therapeutics, 9, 2689-2699.

Poon, K. A., Flagella, K., Beyer, J., Tibbitts, J., Kaur, S., Saad, O., Yi, J.-H., Girish, S., Dybdal, N. & Reynolds, T. 2013. Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicology and Applied Pharmacology, 273, 298-313.

Press, M. F., Cordon-Cardo, C. & Slamon, D. J. 1990. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5, 953-962.

Rx Communications Group, L. 2005. ImmunoGen, Inc. Announces Genentech Has Licensed Rights to Use ImmunoGen's TAP Technology with Therapeutic Antibodies to a Second Target [Online]. Available: https://news.abbvie.com/2005-04-28-ImmunoGen,-Inc-Announces-Genentech-Has-Licensed-Rights-to-Use-ImmunoGens-TAP-Technology-with-Therapeutic-Antibodies-to-a-Second-Target [Accessed 23/10/2024].

Von Minckwitz, G., Huang, C.-S., S. Mano, M., Loibl, S., P. Mamounas, E., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., H. Fischer, H., Jacot, W., K. Conlin, A., Arce-Salinas, C., L. Wapnir, I., Jackisch, C., P. DiGiovanna, M., A. Fasching, P., P. Crown, J., Wülfing, P., Shao, Z., Rota Caremoli, E., Wu, H., H. Lam, L., Tesarowski, D., Smitt, M., Douthwaite, H., M. Singel, S. & E. Geyer, C. 2019. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 380, 617-628.

Wedam, S., Fashoyin-Aje, L., Gao, X., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., King-Kallimanis, B. L., Theoret, M. R., Ibrahim, A., Amiri-Kordestani, L., Pazdur, R. & Beaver, J. A. 2020. FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. Clin Cancer Res, 26, 4180-4185.